9:03AM ISIS Pharm: Roche and Isis Pharmaceuticals form alliance for Huntington's disease; Roche will make an upfront payment of $30 million to Isis (ISIS) 17.37 : Roche (RHHBY) and ISIS announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's proprietary "brain shuttle" program with the objective of increasing the brain penetration of ASOs with systemic administration.
Under the terms of the agreement, Roche will make an upfront payment of $30 million to Isis, with total payments related to license fee and pre- and post-licensing milestone payments reaching potentially $362 million, including up to $80 million in potential commercial milestone payments.
In addition, Isis will receive tiered royalties on sales of the drugs. Roche has the option to license the drugs from Isis through the completion of the first Phase 1 trial. Prior to option exercise, Isis is responsible for the discovery and development of an antisense drug targeting HTT protein.
Roche and Isis will work collaboratively on the discovery of an antisense drug utilizing Roche's "brain shuttle" program. If Roche exercises its option, it will be responsible for global development, regulatory and commercialization activities for all drugs arising out of the collaboration.
ISIS is halted
Market Data 
Markets 
AI
